This downregulation often occurs through genetic mutations or epigenetic alterations in β2-microglobulin or defects in transporter associated with antigen processing (TAP) proteins that prevent the proper loading of tumour-derived peptides onto MHC class I molecules, thereby rendering the tumour cells invisible to CTLs [125, 126]. Here, HLA-G is linked to neoplasm.